Baseline: 46.2 percent of adults aged 18 years and over with diagnosed diabetes and chronic kidney disease received recommended medical treatment with ACE inhibitors or ARBs in 2013-16
Number of adults aged 18 years and over with diagnosed diabetes and chronic kidney disease stages 1–4 who have at least one prescription for an ACE inhibitor or an ARB.
Number of adults aged 18 years and over with diagnosed diabetes and chronic kidney disease stages 1–4.
Minimal statistical significance
Target-setting method details
Minimal statistical significance, assuming the same standard error for the target as for the baseline.
Target-setting method justification
Trend data were not available for this objective. The standard error was used to calculate a target based on minimal statistical significance, assuming the same standard error for the target as for the baseline. This method was used because the target is a statistically significant improvement from the baseline. Patient care guidelines from the National Kidney Foundation and the American Diabetes Association and national efforts such as the Million Hearts Initiative make the target realistic to achieve.
Comparable HP2020 objective
Modified, which includes core objectives that are continuing from Healthy People 2020 but underwent a change in measurement.
Changes between HP2020 and HP2030
This objective differs from Healthy People 2020 objective CKD-5 in that CKD-5 used data from the United States Renal Data System (USRDS) to track general Medicare patients age 65 and over diagnosed with both diabetes and chronic kidney disease (CKD), who were continuously enrolled in the Medicare inpatient/outpatient and physician/supplier program, and were also enrolled in Medicare Part D during the entire year. CKD-5 defined the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) as at least one prescription fill from either drug class during the year. In contrast, objective CKD-2030-5 uses data from the National Health and Nutrition Examination Survey to track persons aged 18 years and over with diagnosed diabetes and CKD. Diabetes diagnosis and prescription medication use are determined using interview questions and CKD diagnosis is based on laboratory testing in the NHANES mobile examination centers.
In 2023, the original baseline was revised from 43.0 to 46.2 percent due to changes to 2021 race free, serum creatine only CKD-EPI equation used to determine estimated glomerular filtration rate (eGFR). The target was adjusted from 55.4 to 58.6 percent to reflect the revised baseline using the original target-setting method.